PT  - JOURNAL ARTICLE
AU  - H. Juliette T. Unwin
AU  - Lazaro Mwandigha
AU  - Peter Winskill
AU  - Azra C. Ghani
AU  - Alexandra B. Hogan
TI  - Analysis of the potential for a malaria vaccine to reduce gaps in malaria intervention coverage
AID  - 10.1101/2020.10.09.20209973
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.09.20209973
4099  - http://medrxiv.org/content/early/2020/10/13/2020.10.09.20209973.short
4100  - http://medrxiv.org/content/early/2020/10/13/2020.10.09.20209973.full
AB  - Background The RTS,S/AS01 malaria vaccine is currently being piloted in three African countries. We sought to identify whether vaccination could reach additional children who are at risk from malaria but do not currently have access to, or use, core malaria interventions.Methods Using data from household surveys we calculated the overlap between malaria intervention coverage and childhood vaccination (diphtheria-tetanus-pertussis dose 3, DTP3) uptake in 20 African countries with at least one first administrative level unit with Plasmodium falciparum parasite prevalence greater than 10%. We used multilevel logistic regression to explore patterns of overlap by demographic and socioeconomic variables. We also estimated the public health impact of delivering RTS,S/AS01 to those children who do not use an insecticide-treated net (ITN) but who received the DTP3 vaccine.Results Uptake of DTP3 was higher than malaria intervention coverage in most countries. Overall, 34% of children did not use ITNs and received DTP3, while 35% of children used ITNs and received DTP3, although this breakdown varied by country. We estimated that there are 33 million children in these 20 countries who do not use an ITN. Of these, 23 million (70%) received the DTP3 vaccine. Vaccinating those 23 million children who receive DTP3 but do not use an ITN could avert an estimated 9.7 million clinical malaria cases each year. An additional 10.8 million cases could be averted by vaccinating those 24 million children who receive the vaccine and use an ITN. Children who had access to or used an ITN were 9 to 13% more likely to reside in rural areas compared to those who had neither intervention regardless of vaccination status. Mothers’ education status was a strong predictor of intervention uptake and was positively associated with use of ITNs and vaccination uptake and negatively associated with having access to an ITN but not using it. Wealth was also a strong predictor of intervention coverage.Conclusions Childhood vaccination to prevent malaria has the potential to reduce inequity in access to existing malaria interventions and could substantially reduce the childhood malaria burden in sub-Saharan Africa, even in regions with lower existing DTP3 coverage.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by grants from PATH (ABH, ACG) and the Bill and Melinda Gates Foundation (HJTU, LM, ACG). HJTU, PW and ABH acknowledge support from their Imperial College Research Fellowships. All authors acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID), under the MRC/DFID Concordat agreement and part of the EDCTP2 programme supported by the European Union.. PATH contributed to the interpretation of results and provided comments on the manuscript. All other funders of the study had no role in study design, data analysis, interpretation of findings, or drafting of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the DHS Program repository (https://dhsprogram.com/) and can be accessed upon registration and application. https://dhsprogram.com/ WHOWorld Health OrganizationGTSWorld Health Organization Global Technical Strategy for MalariaITNinsecticide-treated netDTP3diphtheria-tetanus-pertussis vaccine dose 3IRSindoor residual sprayingRTS,SRTS,S/AS01 malaria vaccine for childrenDHSDemographic and Health SurveysMISMalaria Indicator SurveysEPIExpanded Programme on ImmunizationMAPMalaria Atlas ProjectPfPR2-10P. falciparum parasite prevalence in 2–10-year-old individualsIQRinter-quartile range.